Stock Scorecard
Stock Summary for Aurinia Pharmaceuticals Inc (AUPH) - $8.15 as of 11/20/2024 7:47:06 PM EST
Total Score
14 out of 30
Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for AUPH
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AUPH
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AUPH
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AUPH
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for AUPH (34 out of 90)
Stock Price Rating (Max of 10) | 4 |
Historical Stock Price Rating (Max of 10) | 5 |
Stock Price Trend (Max of 10) | 2 |
Book Value (Max of 10) | 3 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 3 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 4 |
Trading Volume (Max of 10) | 9 |
Price to Earnings (Max of 10) | 0 |
Latest News for for AUPH
Financial Details for AUPH
Company Overview |
|
---|---|
Ticker | AUPH |
Company Name | Aurinia Pharmaceuticals Inc |
Country | USA |
Description | Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | 2/13/2025 |
Stock Price History |
|
Last Day Price | 8.15 |
Price 4 Years Ago | 13.83 |
Last Day Price Updated | 11/20/2024 7:47:06 PM EST |
Last Day Volume | 1,260,889 |
Average Daily Volume | 1,157,930 |
52-Week High | 9.74 |
52-Week Low | 4.71 |
Last Price to 52 Week Low | 73.04% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 22.60 |
Sector PE | 40.32 |
5-Year Average PE | 6.88 |
Free Cash Flow Ratio | 3.35 |
Industry Free Cash Flow Ratio | 12.03 |
Sector Free Cash Flow Ratio | 27.97 |
Current Ratio Most Recent Quarter | 5.60 |
Total Cash Per Share | 2.43 |
Book Value Per Share Most Recent Quarter | 2.71 |
Price to Book Ratio | 3.00 |
Industry Price to Book Ratio | 5.31 |
Sector Price to Book Ratio | 20.88 |
Price to Sales Ratio Twelve Trailing Months | 5.28 |
Industry Price to Sales Ratio Twelve Trailing Months | 11.82 |
Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
Analyst Buy Ratings | 3 |
Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
Total Shares Outstanding | 143,179,000 |
Market Capitalization | 1,166,908,850 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 27.88% |
Reported EPS 12 Trailing Months | -0.15 |
Reported EPS Past Year | 0.08 |
Reported EPS Prior Year | -0.54 |
Net Income Twelve Trailing Months | -22,552,000 |
Net Income Past Year | -78,020,000 |
Net Income Prior Year | -108,180,000 |
Quarterly Revenue Growth YOY | 24.30% |
5-Year Revenue Growth | 226.86% |
Operating Margin Twelve Trailing Months | 0.17 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 348,235,000 |
Total Cash Past Year | 350,369,000 |
Total Cash Prior Year | 389,306,000 |
Net Cash Position Most Recent Quarter | 348,235,000 |
Net Cash Position Past Year | 350,369,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 377,954,000 |
Total Stockholder Equity Prior Year | 405,435,000 |
Total Stockholder Equity Most Recent Quarter | 388,002,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | 28,302,000 |
Free Cash Flow Per Share Twelve Trailing Months | 0.20 |
Free Cash Flow Past Year | -34,179,000 |
Free Cash Flow Prior Year | -79,821,000 |
Options |
|
Put/Call Ratio | 0.07 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.34 |
MACD Signal | 0.28 |
20-Day Bollinger Lower Band | 5.10 |
20-Day Bollinger Middle Band | 6.82 |
20-Day Bollinger Upper Band | 8.55 |
Beta | 1.46 |
RSI | 62.28 |
50-Day SMA | 6.49 |
150-Day SMA | 8.63 |
200-Day SMA | 10.75 |
System |
|
Modified | 11/20/2024 6:29:16 PM EST |